Pharmaceuticals - Community Register

  

Community register of veterinary medicinal products


AUTHORISED  

Product information

Invented name: Palladia   
Auth. number : EU/2/09/100
Active substance : Toceranib
ATC: Anatomical main group: QL - Antineoplastic and immunomodulating agents
Therapeutic subgroup: QL01 - Antineoplastic Agents
Pharmacological subgroup: QL01X - Other antineoplastic agents
Chemical subgroup: QL01XE - Protein kinase inhibitors
Chemical substance: QL01XE91 - Toceranib
(See WHO ATCvet Index)
Indication: Treatment of non-resectable Patnaik grade II (intermediate grade) or III (high grade), recurrent, cutaneous mast cell tumours in dogs
Marketing Authorisation Holder: Zoetis Belgium S.A.
Rue Laid Burniat 1, 1348 Louvain-la-Neuve, Belgique
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
25/09/2009 Centralised - Authorisation EMEA/V/C/150 (2009)7454 of 23/09/2009
27/05/2010 Centralised - Variation EMEA/V/C/150/IB/1
Updated with Decision(2011)192 of 13/01/2011
03/12/2010 Centralised - Variation EMEA/V/C/150/IG/2/G
Updated with Decision(2011)5064 of 07/07/2011
17/01/2011 Centralised - Variation (2011)192 of 13/01/2011
16/02/2011 Centralised - Variation EMEA/V/C/150/IB/2
Updated with Decision(2011)5064 of 07/07/2011
12/07/2011 Centralised - Variation (2011)5064 of 07/07/2011
29/05/2013 Centralised - Transfer Marketing Authorisation Holder EMEA/V/C/150/T/5 (2013)3223 of 27/05/2013
04/08/2014 Centralised - Renewal EMEA/V/C/150/R/7 (2014)5630 of 31/07/2014
06/03/2015 Centralised - Variation EMEA/V/C/150/IB/9